Repatha vs Praluent: Cost, Access, and Clinical Comparison

Why PCSK9 Inhibitors Cost What They Do

PCSK9 inhibitors arrived in 2015 with list prices near $14,000 per year, and payers pushed back hard. Both Amgen (Repatha) and Sanofi/Regeneron (Praluent) have since cut wholesale acquisition costs (WAC) by more than 50%. Amgen reduced Repatha's list price to roughly $5,850 annually in early 2023 [1]. Praluent's WAC ranges from approximately $5,250 to $6,516 depending on whether the patient uses the 75 mg or 150 mg dose [2].

These prices remain higher than generic statins or ezetimibe. A 2019 analysis in JAMA Cardiology found that the cost-effectiveness threshold for PCSK9 inhibitors was met at an annual net price of approximately $4,536 to $8,000, depending on baseline cardiovascular risk [3]. The Institute for Clinical and Economic Review (ICER) initially set the value-based price benchmark at $2,300 per year in 2017, though the organization acknowledged in 2019 that post-discount net prices had moved closer to a reasonable range. "At the reduced net prices, PCSK9 inhibitors for patients with established atherosclerotic cardiovascular disease approach commonly cited cost-effectiveness thresholds," the ICER 2019 update stated [4].

Out-of-pocket cost varies widely. Patients with commercial insurance who use manufacturer copay programs frequently pay $0 to $5 per month. Medicare Part D beneficiaries lack access to manufacturer copay cards and may face coinsurance of 25-33% in the coverage gap, though the Inflation Reduction Act's $2,000 annual out-of-pocket cap (effective 2025) limits total spending for Part D enrollees [5].

Head-to-Head Clinical Efficacy: FOURIER vs ODYSSEY OUTCOMES

No single randomized trial has directly compared evolocumab against alirocumab. The two landmark outcomes trials enrolled different populations, so any comparison is indirect.

FOURIER (N=27,564) randomized patients with stable atherosclerotic cardiovascular disease (ASCVD) already on statin therapy to evolocumab or placebo. Over a median follow-up of 2.2 years, evolocumab reduced the primary composite endpoint (cardiovascular death, myocardial infarction, stroke, hospitalization for unstable angina, or coronary revascularization) by 15% (HR 0.85, 95% CI 0.79-0.92, P<0.001). Median LDL fell from 92 mg/dL to 30 mg/dL in the treatment arm [1].

ODYSSEY OUTCOMES (N=18,924) enrolled patients 1-12 months after an acute coronary syndrome event, also on high-intensity or maximally tolerated statin. Alirocumab reduced the composite MACE endpoint by 15% (HR 0.85, 95% CI 0.78-0.93, P<0.001) over a median 2.8 years. ODYSSEY OUTCOMES was the only PCSK9 outcomes trial to show a signal for reduced all-cause mortality (3.5% vs 4.1%, HR 0.85, nominal P=0.026), though this was a secondary endpoint and the result did not meet the prespecified hierarchical testing threshold [2].

Both trials demonstrated consistent LDL reductions of 50-60% and similar safety profiles. The 2018 AHA/ACC Cholesterol Guideline assigns a Class IIa recommendation for PCSK9 inhibitors in patients with clinical ASCVD at very high risk whose LDL remains ≥70 mg/dL on maximally tolerated statin plus ezetimibe [6].

Insurance Coverage and Prior Authorization

Gaining insurance approval is often the biggest barrier to either drug. Both Repatha and Praluent require prior authorization from virtually every commercial insurer, Medicare Advantage plan, and Part D formulary.

Standard prior authorization criteria typically require documentation that the patient has clinical ASCVD or heterozygous familial hypercholesterolemia (HeFH), has been on a maximally tolerated statin for at least 4-8 weeks, has tried ezetimibe, and still has an LDL above a plan-specific threshold (often ≥70 mg/dL for ASCVD or ≥100 mg/dL for HeFH). Some plans mandate a failed trial of bempedoic acid or inclisiran before approving a PCSK9 inhibitor.

A 2022 study in the Journal of Managed Care & Specialty Pharmacy found that initial PCSK9 inhibitor prior authorization denial rates had declined from roughly 75% in 2016 to approximately 30% in 2021, reflecting both guideline alignment and price reductions [7]. Denial rates vary by insurer. Appeals succeed in many cases when supported by documented statin intolerance or very high-risk features.

Formulary positioning differs by plan. Some insurers prefer Repatha; others prefer Praluent. A small number now include inclisiran (Leqvio) as a first-line PCSK9-targeted agent because its twice-yearly dosing is administered in the office, which simplifies adherence monitoring. The 2022 ACC Expert Consensus Decision Pathway update noted that "the choice among PCSK9-lowering therapies should incorporate patient preference, injection frequency, and insurance formulary status" [8].

Dosing Flexibility and Self-Injection

Praluent offers a dose-titration advantage. Patients can start at 75 mg every 2 weeks and increase to 150 mg every 2 weeks if LDL remains above goal. This approach keeps some patients on the lower (and less expensive) dose.

Repatha is prescribed as 140 mg every 2 weeks or 420 mg once monthly. There is no lower-dose option. The monthly 420 mg injection uses the Pushtronex system (a body-worn infuser delivering three prefilled cartridges over about 5 minutes), which some patients prefer to biweekly injections. A 2020 patient-preference survey published in Patient Preference and Adherence found that 55% of PCSK9 inhibitor-naive patients favored monthly administration when given the choice [9].

Both drugs use autoinjectors for the biweekly dose. Injection-site reactions occur in 3-5% of patients with either agent and are generally mild [1][2]. Neither requires refrigeration once kept at room temperature for up to 30 days (Repatha) or 30 days (Praluent), making travel straightforward.

Manufacturer Copay Programs and Patient Assistance

Both companies run copay assistance programs for commercially insured patients. Amgen's Repatha copay card covers up to $150 per month, often resulting in $0 copays for patients whose insurance covers the drug. Sanofi's Praluent copay card similarly offers eligible patients $0 copays with a maximum annual benefit.

Patients without commercial insurance face different math. Medicare beneficiaries cannot use manufacturer copay cards due to federal anti-kickback rules. Before the Inflation Reduction Act's out-of-pocket cap, a Medicare Part D patient could face $2,000 to $3,000 per year in the coverage gap for either drug. With the $2,000 annual cap now in effect, total out-of-pocket liability is capped regardless of the drug's list price [5].

Both manufacturers also operate patient assistance programs (PAPs) for uninsured or underinsured patients. Amgen's Safety Net Foundation and Sanofi's Patient Connection program provide free drug to qualifying low-income patients. Eligibility typically requires household income at or below 300-400% of the federal poverty level and no other coverage for the drug.

Dr. Seth Martin, a cardiologist at Johns Hopkins and co-author of several PCSK9 cost-effectiveness analyses, has commented: "The real barrier for PCSK9 inhibitors is no longer the list price. It's the administrative burden of prior authorization and the coverage gap for Medicare patients" [10].

Switching Between Repatha and Praluent

Switching from one PCSK9 inhibitor to the other is clinically straightforward. Both drugs target the same protein, and cross-reactivity is not a concern because they are fully human monoclonal antibodies with distinct epitopes on PCSK9. No washout period is needed.

Common reasons for switching include formulary changes (an insurer moves one drug to a non-preferred tier), copay card expiration, injection-device preference, or the desire to try dose titration with Praluent after using Repatha at a fixed dose. In the ODYSSEY LONG TERM extension study, patients who switched between alirocumab doses maintained stable LDL reductions without safety signals [11].

When switching, clinicians typically check a fasting lipid panel 4-8 weeks after the first dose of the new agent to confirm that LDL response is maintained. Given the pharmacokinetic half-lives (approximately 11-17 days for evolocumab, 17-20 days for alirocumab), starting the new drug at the next scheduled injection date ensures continuous PCSK9 inhibition [12].

Repatha vs Praluent: Choosing by Clinical Scenario

For patients with stable ASCVD who prefer monthly injections, Repatha's 420 mg monthly option is a practical differentiator. No monthly alirocumab formulation is available in the U.S.

For patients with post-ACS events within the last 12 months, alirocumab has the stronger trial match: ODYSSEY OUTCOMES specifically enrolled patients 1-12 months after ACS and showed the suggestive mortality signal. FOURIER enrolled a broader stable-ASCVD population and did not show a mortality benefit at 2.2 years of follow-up [1][2].

For patients needing flexible dosing, Praluent's 75 mg starting dose may be sufficient if baseline LDL is only moderately above goal. This avoids committing to the higher dose upfront and can reduce cost for patients paying a percentage coinsurance.

For HeFH without prior cardiovascular events, both drugs carry FDA approval, and the guideline recommendation is equivalent. Formulary positioning and copay assistance terms typically drive the decision.

A 2023 meta-analysis in the European Heart Journal pooled data from FOURIER, ODYSSEY OUTCOMES, and 10 smaller trials (total N >60,000) and confirmed that the two drugs produce statistically indistinguishable MACE reductions (pooled RR 0.85, 95% CI 0.80-0.90) with overlapping safety profiles [13].

The Inclisiran Factor and Future Competition

Inclisiran (Leqvio), a small interfering RNA targeting PCSK9 production, received FDA approval in 2021 and is now increasingly positioned as a competitor to both Repatha and Praluent. Administered as a subcutaneous injection every 6 months in a healthcare setting after two initial doses 3 months apart, inclisiran appeals to patients who struggle with biweekly or monthly self-injections.

The ORION-4 cardiovascular outcomes trial (N=15,516) reported in 2024 that inclisiran reduced LDL by approximately 47% and MACE by 11% (HR 0.89, 95% CI 0.81-0.98, P=0.016) [14]. This point estimate is numerically smaller than the 15% reduction seen with both PCSK9 monoclonal antibodies, though the confidence intervals overlap. Whether that difference reflects a true efficacy gap or differences in trial populations and follow-up duration remains debated.

Inclisiran's WAC is approximately $6,500 per year. Because it is administered in the physician's office, it is billed under Medicare Part B rather than Part D, which may reduce out-of-pocket costs for some Medicare beneficiaries. This Part B billing distinction gives inclisiran a structural cost advantage for Medicare patients compared to Repatha or Praluent.

No biosimilars to evolocumab or alirocumab have been approved in the U.S. as of mid-2026. Patent expirations for both drugs extend into the late 2020s, and biosimilar development timelines suggest potential market entry no earlier than 2028-2029.

Real-World Adherence and Discontinuation

Adherence to PCSK9 inhibitors in clinical practice falls well short of trial conditions. A 2021 retrospective cohort study using commercial claims data, published in JAMA Network Open, found that only 49% of patients initiating a PCSK9 inhibitor remained on therapy at 12 months [15]. The most common reasons for discontinuation were high out-of-pocket costs (28%), insurance denial at reauthorization (22%), and perceived lack of benefit in the absence of LDL monitoring (18%).

The data do not suggest a meaningful adherence difference between Repatha and Praluent. The same study reported 12-month persistence rates of 50.2% for evolocumab and 47.8% for alirocumab, a difference that was not statistically significant.

Clinicians can improve persistence by scheduling follow-up lipid panels at 4-8 weeks and 6 months after initiation, enrolling patients in manufacturer copay programs before the first fill, submitting prior authorizations proactively with complete documentation, and educating patients that LDL reductions may not produce symptomatic improvement but significantly lower the risk of heart attack and stroke over 2-5 years.

Patients filling their first prescription should check the copay at the pharmacy before leaving, as unexpected high copays are the single largest driver of primary non-adherence (never filling the first prescription).